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Abstract 
Introduction 
Non-small cell lung cancer (NSCLC) arises when epithelial cells lining the 
bronchial tubes undergo aberrant cell growth. Ceritinib is recommended as 
first-line treatment for adults with anaplastic lymphoma kinase (ALK)-
positive advanced NSCLC based on its’ recent approval by the US Food and 
Drug Administration (FDA) and positive opinion by the European Commit-
tee for Medicinal Products for Human Use (CHMP). Ceritinib is also indi-
cated for patients with disease progression or intolerance to crizotinib. By 
supressing the phosphorylation of ALK, ceritinib, a second-generation ALK 
inhibitor (ALKi), prevents the proliferation of ALK-positive NSCLC cells.  
Methodology  
Published and grey literature were identified by searching the Cochrane Li-
brary, CRD Database, Embase, Ovid Medline, PubMed, Internet sites and 
contacting the manufacturer. Quality assessment was conducted to assess 
the risk of bias at the study level based on the EUnetHTA internal validity 
for randomized controlled trials. Furthermore, the magnitude of clinically 
meaningful benefit that can be expected from ceritinib was evaluated based 
on, both the original and an adapted versions of, the Magnitude of Clinical 
Benefit Scale developed by the European Society for Medical Oncology. 
Results of the ASCEND-4 trial 
Between 19 August 2013 and 11 May 2015, an intent-to-treat (ITT) popula-
tion of 376 untreated ALK-rearranged NSCLC patients were randomly as-
signed to receive either ceritinib (n = 189) or platinum-based chemotherapy 
(n= 187). Ceritinib increased the primary endpoint of progression-free sur-
vival (PFS) in the ITT population by 8.5 months and duration of response 
(DOR) by 12.8 months, compared with chemotherapy. While overall surviv-
al (OS) data were immature at the time of analysis, the estimated OS rate at 
24 months was 71% with ceritinib and 58% with chemotherapy. In patients 
with measureable brain metastases (BM) at baseline, 73% of ceritinib and 
27% of chemotherapy recipients achieved an overall intracranial response 
(OIRR). Treatment-related adverse events (AEs) were more commonly re-
ported in the ceritinib group; while 50 (28%) of dose adjustments or inter-
ruptions occurred due to gastrointestinal (GI) toxicity, ceritinib also in-
creases the risk of hepatotoxicity, pancreatitis and cardiac arrhythmias.  
Conclusion 
Overall, ceritinib increases PFS and DOR in untreated ALK-positive 
NSCLC, regardless of the presence or absence of baseline BM, relative to 
platinum-based chemotherapy. Ceritinib also improved general quality of 
life (QoL) and prolonged time to deterioration of cancer-specific symptoms 
compared to chemotherapy. However, results from ASCEND-4 hold limited 
external validity as crizotinib is now standard care over chemotherapy for 
ALK-positive NSCLC and it is unclear whether increased PFS actually con-
fers a meaningful change in OS. Even in the absence of head-to-head com-
parison trials and despite the lack of OS benefit, oncologists may chose 
ceritinib as first-line therapy for patients with advanced ALK-positive 
NSCLC if it is more active than other drugs even if it is less tolerable. Com-
parative studies of other second- and third-generation ALKi are ongoing 
which may offer further first-line options.  
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1 Research questions 
The HTA Core Model
®
 for Rapid Relative Effectiveness Assessment of 
Pharmaceuticals was used for structuring this report[1]. The Model organis-
es HTA information according to pre-defined generic research questions. 
Based on these generic questions, the following research questions were an-
swered in the assessment. 
 
 
 
 
 
 
 
 
EUnetHTA 
HTA Core Model® 
Element ID Research question 
Description of the technology 
B0001 What is ceritinib? 
A0022 Who manufactures ceritinib? 
A0007 What is the target population in this assessment? 
A0020 For which indications has ceritinib received marketing authorisation? 
Health problem and current use 
A0002 What is NSCLC? 
A0004 What is the natural course of NSCLC? 
A0006 What are the consequences of NSCLC for the society? 
A0023 How many people belong to the target population? 
A0005 What are the symptoms and the burden of NSCLC? 
A0003 What are the known risk factors for NSCLC? 
A0024 How is NSCLC currently diagnosed according to published guidelines and in practice? 
A0025 How is NSCLC currently managed according to published guidelines and in practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of ceritinib? 
D0005 How does ceritinib affect symptoms and findings (severity, frequency) of NSCLC? 
D0006 How does ceritinib affect progression (or recurrence) of NSCLC? 
D0011 What is the effect of ceritinib on patients’ body functions? 
D0012 What is the effect of ceritinib on generic health-related quality of life? 
D0013 What is the effect of ceritinib on disease-specific quality of life? 
Safety 
C0008 How safe is ceritinib in relation to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying ceritinib? 
C0005 
What are the susceptible patient groups that are more likely to be harmed through the 
use of ceritinib? 
A0021 What is the reimbursement status of ceritinib? 
Horizon Scanning in Oncology 
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2 Drug description 
Generic/Brand name/ATC code:  
Ceritinib/Zykadia
®
/LDK378 
 
B0001: What is ceritinib? 
In a subset of non-small cell lung cancers (NSCLC), a chromosomal rear-
rangement fuses the anaplastic lymphoma kinase (ALK) gene with the echi-
noderm microtubule-associated protein-like 4 (EML4) gene. The resulting 
EML4-ALK fusion oncogene produces a protein with constitutive kinase ac-
tivity conferring uncontrolled cell growth [2, 3]. Ceritinib, a highly selective 
second-generation ALK inhibitor (ALKi), suppresses the phosphorylation of 
ALK thereby inhibiting proliferation of ALK-positive cancer cells [4, 5]. 
ALK-positive means that the cancer cells have certain defects affecting the 
gene responsible for the ALK protein. 
Ceritinib is available as a 150 mg oral capsule. The recommended dose for 
ALK-positive metastatic NSCLC is 750 mg (five capsules) once daily until 
disease progression or unacceptable toxicity. Ceritinib is administered at 
least one hour before or two hours after a meal [6].  
Patients require monthly liver function tests and periodic lipase and/or am-
ylase testing due to the risks for hepatotoxicity and pancreatitis. Dose inter-
ruption and reduction is recommended for individuals with hyperglycaemia 
or gastrointestinal (GI) adverse reactions. Ceritinib may be discontinued in 
patients with pneumonitis, cardiac arrhythmias, hepatotoxicity or intoler-
ance at a dosage of 300 mg/day due to adverse drug reactions. Concomitant 
use of strong CYP3A inhibitors or inducers should be avoided [6].  
 
A0022: Who manufactures ceritinib? 
Novartis Pharmaceuticals 
 
 
 
3 Indication 
A0007: What is the target population in this assessment? 
Ceritinib (Zykadia
®
) is indicated as first-line therapy for patients with 
ALK-rearranged (ALK-positive) NSCLC.  
 
 
 
second-generation ALKi 
750 mg orally once daily 
liver function/ lipase 
testing interrupt/reduce 
dose for 
safety/tolerability 
treatment naïve 
advanced ALK-
rearranged (ALK-
positive) NSCLC 
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4 Current regulatory status 
A0020: For which indications has ceritinib received marketing authorisa-
tion? 
In April 2014, the US Food and Drug Administration (FDA) granted accel-
erated approval of ceritinib for the treatment of patients with ALK-positive 
NSCLC with disease progression on or intolerance to the first-line ALKi 
crizotinib [7]. Initial approval was based on the results of the phase I, single-
arm, open-label ASCEND-1 trial [8]. 
In January 2017, the FDA granted ceritinib breakthrough therapy designa-
tion as first-line treatment for patients with ALK-positive NSCLC with 
brain metastases (BM), and priority review as first-line ALK-positive meta-
static NSCLC. On May 26, 2017, the FDA expanded the use of ceritinib to 
include first-line treatment of patients with ALK-positive metastatic 
NSCLC as detected by an FDA-approved test (Vysis ALK Break Apart 
FISH Probe Kit and Ventana ALK [D5F3] CDx assay) [9]. The first-line 
approval of ceritinib was based on results from the phase III ASCEND-4 tri-
al [10].  
Ceritinib received marketing authorisation by the European Medicines 
Agency (EMA) in May 2015 for the treatment of adults with ALK-positive 
advanced NSCLC previously treated with crizotinib [11]. On May 18, 2017, 
the Committee for Medicinal Products for Human Use (CHMP) adopted a 
positive opinion recommending ceritinib monotherapy for the first-line 
treatment of adult patients with ALK-positive advanced NSCLC [12]. 
 
 
 
5 Burden of disease 
A0002: What is NSCLC? 
NSCLC is the most common epithelial lung cancer and accounts for approx-
imately 80–85% of all lung cancers. Adenocarcinoma, the most common his-
tological type, has a survival rate of approximately 5–6% at 5 years [13, 14]. 
ALK-positive tumours represent a subset of adenocarcinomas characterized 
by a solid growth pattern and signet ring cell cytomorphology or mucinous 
cribriform pattern. Radiologic features associated with ALK-positivity in-
clude central tumour location, lack of pleural tail sign, and pleural effusion 
[2].  
ALK rearrangements occur in approximately 4–5% of NSCLC patients, al-
most never co-occurring with epidermal growth factor receptor (EGFR) or 
Kirsten rat sarcoma viral oncogene (KRAS) mutations [15]. Multiple EML4-
ALK variants have been identified with variations in truncations of EML4 
on different exons but all include a functioning kinase domain [15]. Com-
pared to EGFR-positive NSCLC, patients with ALK-positive tumours are 
most likely male, and are associated with larger-volume, multifocal thoracic 
lymphadenopathy [15-17].  
FDA: licensed as 2nd-
line in April 2014 
FDA: licensed as 1st-line 
in May 2017 
EMA: marketing 
authorisation for ALK-
positive NSCLC post 
crizotinib in May 2015; 
pos. CHMP for first-line 
treatment in May 2017  
NSCLC accounts for 80–
85% of all lung cancers 
ALK rearrangement in 
5% of NSCLC patients 
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A0004: What is the natural course of NSCLC? 
Lung cancer typically arises when epithelial cells lining the bronchial tubes 
undergo aberrant cell growth. To decide on the most appropriate treatment, 
lung cancer is staged from I through IV based on tumour size, and presence 
or absence of lymph node involvement and metastases (TNM). Stage I lung 
cancer is <3 cm and localized to one lobe; stage II has spread to other parts 
of the lung or lymph nodes; stage III may be large or spread to lymph nodes 
between the lungs; and stage IV has metastasized to the adjacent lung, brain, 
liver or bones [13, 18]. NSCLC patients harbouring EML4-ALK mutations 
typically have more advanced disease than unselected patients [19], with 
predilection for brain and liver metastases [20]. 
 
A0006: What are the consequences of NSCLC for the society? 
Lung cancer is the second most frequently diagnosed cancer. While the im-
plementation of smoking cessation programs and multidisciplinary treat-
ments have reduced the incidence and mortality, 52–58% of lung cancer pa-
tients present with advanced-stage disease when curative treatment is no 
longer feasible. ALK-positivity is a poor prognostic factor in NSCLC [15], 
leading to a high rate of relapse and early formation of micro-metastases 
[21].  
 
A0023: How many people belong to the target population? 
Lung cancer is the leading cause of cancer-related death in men and the sec-
ond in women worldwide. The age standardized incidence rate for the Euro-
pean Standard Population was 56.9 per 100,000 persons per year in 2013. In 
Austria, 2,894 men and 1,822 women were newly diagnosed with lung cancer 
in 2014; and 3,908 men and 2,450 women died due to lung cancer (47.3 per 
100,000 persons per year) [22]. Approximately 6.5% of people will be diag-
nosed with lung cancer during their lifetime and at least a third of newly di-
agnosed patients have distant metastases. While the average age at diagnosis 
is approximately 70 years in unselected patients [14], ALK-positive NSCLC 
patients are younger at onset with a median age of 52 years [15, 17]. In unse-
lected NSCLC populations, defects in the ALK gene are relatively rare with 
an overall incidence of 4–7% [17].  
 
A0005: What are the symptoms and the burden of NSCLC? 
Many lung cancers are not symptomatic until they have spread. Symptoms 
of NSCLC include incessant cough, bloody sputum, chest pain, wheezing or 
hoarseness, weight loss or loss of appetite, shortness of breath, fatigue, and 
recurrent bronchitis or pneumonia. ALK-positive NSCLC most commonly 
metastasizes to brain and liver causing pain, headaches, improper balance, 
seizures, or jaundice [13, 20].  
 
 
 
 
staged I–IV by 
invasiveness 
 
 
 
most commonly 
metastasize to brain and 
liver 
52–58% present with 
advanced cancer; 
relapse and metastasize 
early 
4,716 Austrians were 
diagnosed with NSCLC 
in 2014 
ALK-positive NSCLC 
diagnosed at median 
age of 52 years  
NSCLC symptoms: 
cough, chest pain, 
weight loss, shortness of 
breath 
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A0003: What are the known risk factors for NSCLC? 
The risk of lung cancer typically increases with age, tobacco use, radiation 
exposure, air pollution, and occupational exposure to asbestos, arsenic, 
chromium beryllium, nickel and other agents [13]. Despite a vast majority of 
NSCLC being associated with mutations induced through tobacco exposure, 
ALK-positive NSCLC is most prevalent in non-smokers [3, 15-17].  
 
A0024: How is NSCLC currently diagnosed according to published guide-
lines and in practice? 
While some lung cancers may be found through screening, most are identi-
fied when they become symptomatic. Following a clinical history and physi-
cal exam, a chest x-ray may be done to identify any abnormal areas in the 
lungs. A computed tomography (CT) scan may show the size, shape and lo-
cation of any lung tumours or enlarged lymph nodes, and guide a needle bi-
opsy if a suspected area is identified. Lung cancer is diagnosed by examin-
ing cells derived through biopsy or sputum sampling for the presence of 
cancer cells [18].  
Diagnostic methods most commonly used to identify ALK gene rearrange-
ments in biopsy samples include fluorescence in situ hybridization (FISH) 
and immunohistochemistry (IHC) [2, 23]. Due to the ability to visualize re-
arrangements using dual colour, FISH with break-apart probes has become 
a reference standard for assessing ALK-positive NSCLC [2, 15]. IHC is rap-
id and relatively inexpensive, however the sensitivity and specificity of IHC 
ALK testing ranges from 67-100% and 93-100%. A two-tiered approach may 
be used where patients undergo initial IHC screening; those with moderate 
or intense staining may undergo further testing with FISH to confirm ALK 
positivity [2]. Next generation sequencing (NGS) may identify ALK rear-
rangements not previously identified through FISH and co-occurring driver 
mutations that may provide further clinical value [16, 24]. FISH and IHC 
are approved by the US FDA as companion diagnostic tests to identify ALK-
positive NSCLC (Vysis ALK Break Apart FISH Probe Kit; Ventana ALK 
(D5F3) CDx assay) [25]. In Europe, IHC is widely used to detect ALK rear-
rangements [17].  
 
 
 
6 Current treatment 
A0025: How is NSCLC currently managed according to published guide-
lines and in practice? 
Depending on the tumour stage, histology, and the patient’s overall health, 
surgery, radiation therapy and/or platinum-based chemotherapy may be 
used alone or in combination to treat NSCLC [18].  
 Stage I and II NSCLC patients typically undergo surgery to remove 
the cancer. Stage II patients may benefit from postoperative adjuvant 
chemotherapy.  
ALK-positive NSCLC is 
associated with never or 
light smoking (<10 
pack-years) 
diagnosis: x-ray, CT and 
biopsy 
ALK status: FISH or IHC 
NGS identifies 
rearrangements missed 
by FISH and co-
occurring mutations 
treatment by stage: 
surgery, radiation 
therapy, chemotherapy 
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 Patients with stage I or II cancers that are not surgical candidates, 
due to co-morbidities or limited lung function, may undergo local ra-
diation therapy.  
 Stage III NSCLC patients are highly heterogeneous and may undergo 
a combination of treatments depending on the extent and localization 
of disease as well as prior treatments.  
 Patients with stage IV disease are treated with systemic therapy or a 
symptom-based palliative approach.  
 
In appropriately selected patients, chemotherapy, molecularly targeted ther-
apy, and/or immunotherapy may extend survival. Patients with adenocarci-
noma should be assessed for EGFR and ALK mutations to identify subsets 
likely to respond to inhibitors [18]. ALKi treatment is limited to patients 
with ALK-positive tumours as demonstrated by FISH or IHC using FDA-
approved tests [17].  
 Combination chemotherapy with a platinum-based doublet or im-
munotherapy may be used as initial systemic treatment for patients 
with advanced NSCLC whose tumour does not have a driver muta-
tion.  
 While an ALKi is preferred as first-line therapy for ALK-positive 
NSCLC, some countries restrict ALKi to patients who have pro-
gressed following chemotherapy [18]. When ALK-positive advanced 
NSCLC patients require chemotherapy, most patients appear to ben-
efit more from pemetrexed than taxanes. 
 First-line treatment with ALKi crizotinib is recommended over 
chemotherapy for patients with advanced ALK-positive NSCLC 
without central nervous system (CNS) disease.  
 In the US and Japan, initial treatment with the second-generation, 
CNS-penetrable ALKi alectinib is used to treat patients with ad-
vanced ALK-positive NSCLC with CNS disease at diagnosis. Radia-
tion or surgery may also be indicated for BM.  
 Second-generation ALKi alectinib or ceritinib may be used to treat 
ALK-positive NSCLC patients who develop resistance or intolerance 
to crizotinib. While preference may be given to alectinib given CNS 
and systemic efficacy and tolerability, any second-generation agent 
may be used in the absence of head-to-head comparisons [17].  
 
 
 
7 Evidence 
A literature search was conducted on 12 May 2017 in five databases: the 
Cochrane Library, CRD Database, Embase, Ovid Medline and PubMed. 
Search terms were “Ceritinib”, “Zykadia”, “NSCLC”, “non-small cell lung 
cancer”, “first line” and “advanced”. The manufacturer was also contacted 
and submitted four references (all of which had already been identified by 
systematic literature search). A manual search yielded three FDA reports [6, 
9, 25], two EMA reports [11, 12], four clinical guidance documents [13, 17, 
 
 
 
premetrexed: preferred 
chemotherapy 
 
 
 
first-line ALKi 
recommended over 
chemotherapy in ALK-
positive NSCLC without 
CNS disease 
 
 
 
second-generation ALKi 
alectinib for ALK-
positive NSCLC with 
CNS disease 
systematic literature 
search in 5 databases: 
295 hits 
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18, 21], two statistical documents [14, 22], and a cost document [26]. Ongo-
ing trials information was found on clinicaltrials.gov and EU Clinical Trials 
Register. Overall, 296 references were identified.  
Included in this reported are:  
 ASCEND-4, phase III [10, 27-29] 
 ASCEND-1, phase I [8, 30, 31] 
 ASCEND-3, phase II [32] 
To assess the risk of bias at the study level the assessment of the methodo-
logical quality of the evidence was conducted based on the EUnetHTA in-
ternal validity for randomised controlled trials (RCTs) [33]. Evidence was 
assessed based on the adequate generation of the randomisation sequence, 
allocation concealment, blinding of patient and treating physician, selective 
outcome reporting and other aspects that may increase the risk of bias. 
To evaluate the magnitude of clinically meaningful benefit that can be ex-
pected from a new anti-cancer treatment, the Magnitude of Clinical Benefit 
Scale developed by the European Society for Medical Oncology (ESMO-
MCBS) was used [34]. Additionally, an adapted version (due to perceived 
limitations) of the ESMO-MCBS was applied [35]. Details of the magnitude 
of the clinically meaningful benefit scale are reported in Table 3. 
 
7.1 Clinical efficacy and safety –  
Phase III studies 
ASCEND-4 (NCT01828099) [10, 29] is an open-label, randomized, phase III 
multicentre study involving 376 untreated patients with advanced ALK-
positive non-squamous NSCLC. Efficacy analyses were based on all random-
ly assigned patients comprising the intent-to-treat (ITT) population. Safety 
analyses involved 364 patients who received at least one dose of study drug. 
Study participants were adults with histologically or cytologically confirmed 
stage IIIb/IV non-squamous ALK-positive NSCLC; untreated, with measur-
able disease as per Response Evaluation Criteria in Solid Tumours (RE-
CIST, version 1.1); World Health Organization (WHO) performance status 
0–2; and asymptomatic or neurologically stable BM. ALK-rearrangement 
was determined centrally by the Ventana anti-ALK (D5F3) IHC assay. Pa-
tients were excluded if they had a hypersensitivity to ceritinib or platinum-
containing drugs or a history of interstitial lung disease, concurrent malig-
nancy, uncontrolled heart disease, radiotherapy-related toxicity or impaired 
GI function. Eligible patients were stratified by WHO performance status, 
previous neo-adjuvant or adjuvant chemotherapy, and presence of BM. 
Patients were randomized 1:1 to receive either oral ceritinib (750 mg/day, 
fasted) or platinum-based chemotherapy (cisplatin 75 mg/m
2
 or carboplatin 
AUC 5-6 plus pemetrexed 500 mg/m
2
) IV every 3 weeks for four cycles fol-
lowed by maintenance pemetrexed 500 mg/m
2
) until unacceptable toxicity 
or disease progression. The median duration of treatment exposure was 66.4 
weeks (IQR 30.0–83.7) for ceritinib and 26.9 weeks (13.0–62.3) for chemo-
therapy.  
included: 3 studies 
study level risk of bias 
assessed based on 
EUnetHTA internal 
validity for RCTs 
magnitude of clinically 
meaningful benefit 
assessed based on 
ESMO-MCBS 
ASCEND-4: ceritinib 
versus chemotherapy in 
375 treatment naïve 
ALK-positive NSCLC 
patient 
ITT stratified by WHO 
PS, previous therapy, 
and BM 
ceritinib 750 mg/day vs 
chemotherapy IV every 
3 weeks, 4 cycles, with 
pemetrexed 
maintenance 
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The primary endpoint was progression-free survival (PFS) as assessed by the 
blinded independent review committee (BIRC) according to RECIST 1.1 or 
death due to any cause. Should the primary outcome be met, the secondary 
outcome of overall survival (OS) would be evaluated. Other secondary end-
points included overall response rate (ORR), duration of response (DOR), 
time to response (TTR), overall intracranial response rate (OIRR), duration 
of intracranial response (DIOR), intracranial clinical benefit rate (ICBR), 
patient reported outcomes (PROs), and safety. Tumours were assessed at 
baseline, every 6 weeks after cycle 1 day 1 through month 33, every 9 weeks, 
and at the end of treatment. 
The ITT population (n = 376) had a median age of 54 years (range 22–81), 
43% were male, 54% were Caucasian, 97% had adenocarcinoma, 96% were 
stage IV NSCLC at entry and 61% had never smoked. Approximately 17/376 
(5%) of participants had prior adjuvant chemotherapy, 77/376 (21%) had 
radiation therapy, and 50/121 (41%) had brain radiation. Detailed patient 
characteristics, including inclusion and exclusion criteria are reported in 
Table 4 and study quality is described in Table 5 of the appendix, respec-
tively. Clinical efficacy data are presented in Table 1 and adverse events 
(AEs) are listed in Table 2.  
 
7.1.1 Clinical efficacy 
D0001: What is the expected beneficial effect of ceritinib on mortality? 
At the time of analysis, June 24, 2016, the OS data were not mature with 107 
OS events (48 events in the ceritinib group and 59 events in the chemother-
apy group representing 42% of the required events for the final OS analysis. 
The median OS was not reached in the ceritinib group (95% CI 29.3–not es-
timable [NE]) and was 26.2 months (22.8–NE) in the chemotherapy group 
(hazard ratio [HR] 0.73 [95% CI 0.50–1.08]; p = 0.056). At 24 months, the 
estimated OS rates were 70.6 (95% CI 62.6-77.5) for ceritinib recipients and 
58.2% (95% CI 47.6–67.5) for chemotherapy recipients. The study did not 
cross the efficacy stopping boundary for OS (-3.2546 [Z-scale] corresponding 
to p = 0.0006 on the p-value scale). Approximately 105/145 (72% of) pa-
tients received an ALKi after discontinuing chemotherapy, including 80 pa-
tients who received ceritinib after crossing over to ceritinib in the extension 
phase of the study [10].  
 
D0006: How does ceritinib affect progression (or recurrence) of NSCLC? 
Ceritinib patients had a median PFS of 16.6 months (95% CI 12.6–27.2) 
compared to 8.1 months (95% CI 5.8–11.1) for ALK-positive NSCLC pa-
tients treated with pemetrexed-platinum chemotherapy with pemetrexed 
maintenance, as assessed by BIRC [10]. Compared to platinum-based chem-
otherapy, ceritinib improved PFS, as assessed by the BIRC, with an estimat-
ed relative risk reduction of 45% in PFS (HR 0.55 [95% CI 0.42–0.73]; p < 
0.00001) [10].  
The PFS benefit of ceritinib over chemotherapy was also reported in pa-
tients with or without baseline BM. The median PFS, as assessed by the 
BIRC in patients without BM (n = 126, 34%) was 26.3 months (95% CI 
15.4–27.7) in ceritinib patients versus 8.3 months (95% CI 6.0-13.7) in 
chemotherapy patients (HR 0.48 [95% CI 0.33-0.69]). The BIRC-assessed 
primary endpoint: PFS 
secondary endpoints: 
OS, ORR, DOR, TTR, 
OIRR, DIOR, ICBR, 
PROs, and safety 
ITT: median age 54 
years, 97% had 
adenocarcinoma, 61% 
had never smoked 
OS: not mature; only 
42% of required events 
for final analysis  
 
 
24-month OS rates: 
70.6% for ceritinib vs 
58.2% for 
chemotherapy 
median PFS in ITT: 16.6 
months for ceritinib vs 
8.1 months for 
platinum-based 
chemotherapy 
median PFS in patients 
with BM: 10.7 months 
for ceritinib vs 6.7 
months for platinum-
based chemotherapy 
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median PFS in patients with BM (n = 121, 32%) was 10.7 months (95%CI 
8.1-16.4) in the ceritinib group versus 6.7 months (95% CI 4.1-10.6) in the 
chemotherapy group (HR 0.70 [95% CI 0.44-1.12]) [10].  
 
D0005: How does ceritinib affect symptoms and findings (severity, frequen-
cy) of NSCLC? 
The whole body ORR, as assessed by the BIRC, was recorded in 72.5% (95% 
CI 65.5-78.7) of ceritinib recipients versus 26.7% (95% CI 20.5-33.7) of 
chemotherapy recipients [29]. The median TTR was 6.1 weeks (interquartile 
range [IQR] 5.9-6.7, n = 137) for ceritinib and 13.4 weeks (IQR 11.1-29.7, n 
= 50) for chemotherapy. The median DOR was 23.9 months (95% CI 16.6-
NE) in the ceritinib group and 11.1 months (95% CI 7.8-16.4) in the chemo-
therapy group [10].  
OIRR in patients with measurable BM at baseline (n = 44) was 72.7% (95% 
CI 49.8-89.3) for ceritinib recipients versus 27.3% (95% CI 10.7-50.2) for 
chemotherapy recipients. The median DOIR was 16.6 months (95% CI 
8.1-NE) in the ceritinib group and it was not estimable in the chemotherapy 
group because four of six patients had not progressed at the time of analysis. 
The ICBR at 24 weeks or longer was reported in 19 (86.4%) of 22 patients 
(95% CI 65.1-97.1) with ceritinib and 11 (50.0%) of 22 patients (95% CI 
28.2-71.8) with platinum-based chemotherapy [10, 28].  
 
D0011: What is the effect of ceritinib on patients’ body functions? 
Ceritinib may induce liver function abnormalities in some patients. Eleva-
tions in alanine aminotransferase (ALT), aspartate aminotransferase (AST) 
and gamma-glutamyltransferase (GGT) were reported in a total of 60%, 
53%, and 37% of ceritinib recipients, respectively. Increases in amylase and 
lipase were also observed in 37% and 13% of patients receiving ceritinib, re-
spectively. Ceritinib may prolong the QTc interval and lead to an increased 
risk for ventricular tachyarrhythmia or sudden death. Prolonged QTc inter-
vals were observed in 12% of patients treated with ceritinib [6, 10]. 
 
D0012: What is the effect of ceritinib on generic health-related quality of 
life? 
Ceritinib recipients reported improvements in overall health status accord-
ing to the EQ-5D-5L index (p = 0.0006) and a non-significant improvement 
in the EuroQol five dimensions questionnaire visual analogue scale (EQ-5-L 
VAS) (p = 0.053) compared with those treated with platinum-based chemo-
therapy [10].  
 
D0013: What is the effect of ceritinib on disease-specific quality of life? 
PROs in disease-specific symptoms were improved for ceritinib versus 
chemotherapy as assessed by LCSS and QLQ-LC13. Patients receiving 
ceritinib had a longer time to definitive deterioration versus chemotherapy 
for the composite endpoint of lung cancer-specific symptoms of pain, cough, 
and shortness of breath (LCSS, HR 0.61 [95% CI 0.41-0.90]; p = 0.0055 and 
QLQ-LC13, HR 0.48 [95% CI 0.34-0.69]; p < 0.0001). All QLQ-LC-13 symp-
tom scores improved with eight of ten improving significantly versus chemo-
ORR 
ceritinib: 72.5% 
chemotherapy: 26.7%  
median DOR 
ceritinib: 23.9 months 
chemotherapy: 11.1 
months  
 
OIRR 
ceritinib: 72.7%  
chemotherapy: 27.3%  
median DIOR  
ceritinib: 16.6 months 
chemotherapy: NE  
increased risk of 
hepatotoxicity, 
pancreatitis, cardiac 
arrhythmias 
ceritinib improved 
overall health status 
compared to 
chemotherapy 
ceritinib increased the 
time to deterioration 
and improved PROs 
versus chemotherapy 
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therapy. According to the QLQ-C30 instrument, four of five functional do-
mains and six of nine symptom scales improved significantly with ceritinib 
versus chemotherapy. However, two scales related to diarrhoea and nausea 
and vomiting showed less favourable outcomes for ceritinib [10, 28].  
 
Table 1: Efficacy results of ASCEND-4 [10, 27, 28] 
Descriptive statistics 
and estimate variabil-
ity 
Treatment group Ceritinib Chemotherapy 
Number of subject 189 187 
OS events, n (%) 
Median OS, months (95% CI) 
24-month OS rate, % (95% CI) 
48 (25) 
NR (29.3-NE) 
70.6 (62.2-77.5) 
59 (32) 
26.2 (22.8-NE) 
58.2 (47.6-67.5) 
PFS events, n (%)  
Median PFS, months (95% CI) 
Without BM (n = 126) 
With BM (n = 121) 
89 (47) 
16.6 (12.6-27.2) 
26.3 (15.4-27.7) 
10.7 (8.1-16.4) 
113 (60) 
8.1 (5.8-11.1) 
8.8 (6.0-13.7) 
6.7 (4.1-10.6) 
ORR (CR+PR) events, n (%, 95%CI) 
CR, n (%) 
PR, n (%) 
SD, n (%) 
PD, n (%) 
UNK, n (%) 
137 (72.5, 65.5-78.7) 
1 (0.5) 
136 (72.0) 
23 (12.2) 
19 (10.1) 
10 (5.3) 
50 (26.7, 20.5-33.7) 
0 (0) 
50 (26.7) 
88 (47.1) 
26 (13.9) 
23 (12.3) 
Median TTR weeks (range) 6.1 (5.1-61.7) 13.4 (5.1-90.1) 
DOR  
Median DOR, months (95% CI) 
21-month EFR, % (95% CI) 
n = 137 
23.9 (16.6-NE) 
59.0 (49.3-67.4) 
n = 50 
11.1 (7.8-16.4) 
NE 
OIRR by BIRC neuro-radiologist 
OIRR events, n (%, 95% CI) 
CR, n (%) 
PR, n (%) 
SD, n (%) 
PD, n (%) 
UNK, n (%) 
n = 22 
16 (72.7, 49.8-89.3) 
2 (9.1) 
14 (63.6) 
3 (13.6) 
1 (4.5) 
2 (9.1) 
n = 22 
6 (27.3, 10.7-50.2) 
2 (9.1) 
4 (18.2) 
14 (63.6) 
1 (4.5) 
1 (4.5) 
Median DOIR months (95% CI) 16.6 (8.1-NE) NE (1.5-NE) [27] 
ICBR at ≥24 weeks, n (%, 95% CI) 19 (86.4, 65.1-97.1) 11 (50.0, 28.2-71.8) 
Effect estimate per 
comparison 
 
Study endpoint Patient population HR (95% CI), p-value 
PFS by BIRC  
(primary endpoint) 
ITT (n = 376)  
Without BM (n = 126) 
With BM (n = 121) 
0.55 (0.42-0.73), p < 0.00001 
0.48 (0.33-0.69) 
0.70 (0.44-1.12) 
24-month OS rate, % (95% CI) 
(secondary endpoint) 
Data immature at interim analysis 
(42.3% of required events) 
ITT (n = 376) 
105/145 (72%) patients re-
ceived an ALKi after dis-
continuing chemotherapy 
0.73 (0.50-1.08), p = 0.056 
QoL data  
(secondary endpoint) 
EQ-5D-5L  
EQ-5D-5L VAS 
LCSS 
QLQ-LC13 
0.04 (0.02-0.07), p = 0.0006 
2.3 (-0.03-4.59), p = 0.053 
0.61 (0.41-0.90), p = 0.0055 
0.48 (0.34-0.69), p < 0.0001 
Abbreviations: BM = brain metastases, CI = confidence interval, CR = complete response; DOR = duration of response, ED = effect 
difference, EFR = event-free rate, EQ-5D-5L = EuroQol Group 5-dimension self-report questionnaire, HR = hazard ratio, ICBR = 
intracranial benefit rate, LCSS = lung cancer symptom scale, NE = not estimable, NR = not reached, OS = overall survival, PD = 
progressive disease, PFS = progression-free survival, PR = partial response, QLQ-LC13 = lung cancer module, QoL = quality of life, SD = 
stable disease, UNK = unknown, VAS = visual analogue scale 
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7.1.2 Safety 
C0008: How safe is ceritinib in relation to the comparator(s)? 
The most common AEs associated with ceritinib use were diarrhoea (85%), 
nausea (69%), vomiting (66%), hyperglycemia (53%), decreased appetite 
(34%), fatigue (29%), abdominal pain (25%), and cough (24%). AEs sus-
pected to be treatment-related were reported in 184 (97% of) ceritinib recip-
ients and 156 (89% of) patients treated with platinum-based chemotherapy; 
of those 65% (123/189) in the ceritinib group and 40% (70/175) in the 
chemotherapy group were reported as having grade 3 or 4 treatment-related 
AEs. Of these, the most common grade 3 or 4 AEs occurring in >15% of 
ceritinib recipients were increase in ALT (30%), AST (16%) and GGT 
(26%). Pneumonitis was reported in 4 (2%) of patients in the ceritinib group 
and one (1%) of patients in the chemotherapy group. While 11 ceritinib re-
cipients and six chemotherapy recipients died during the on-treatment 
phase, none were suspected to be drug-related [36, 37]. 
 
C0002: Are the harms related to dosage or frequency of applying ceritinib? 
AEs requiring dose adjustment or interruption were reported in 80% of pa-
tients receiving ceritinib and 45% of chemotherapy recipients. Dose adjust-
ment or interruption was primarily due to GI toxicity or liver function ab-
normalities. GI toxicity accounted for 52 (28%) of 189 patients in the 
ceritinib group, including vomiting (29 [15%]), diarrhoea (24 [13%]), nausea 
(22 [12%]) and led 2 patients to discontinue treatment. Most diarrhoea 
events were managed by dose interruption and supportive medication [36, 
37].  
 
C0005: What are the susceptible patient groups that are more likely to be 
harmed through the use of ceritinib? 
Patients with congenital long QT syndrome should avoid using ceritinib. Pa-
tients with congestive heart failure (CHF), bradyarrhythmias, electrolyte 
abnormalities and those on medications that prolong the QT interval should 
undergo periodic electrocardiogram and electrolyte monitoring. As the liver 
metabolizes ceritinib, patients with hepatic impairment may have increased 
exposure. Dose adjustment may be considered for patients with moderate to 
severe hepatic impairment. Patients who develop QT interval prolongation 
in combination with serious arrhythmia, severe hepatotoxicity, inadequate 
hyperglycemic control or pneumonitis while taking ceritinib should perma-
nently discontinue use [37].  
Females are advised to use effective contraception during ceritinib treat-
ment and for 6 months following completion of therapy based on the poten-
tial for foetal toxicity. Women are also advised not to breastfeed during 
treatment and for 2 weeks the last dose. Due to the risk of genotoxicity, 
males are advised to use condoms during treatment and for 3 months follow-
ing therapy [37].  
 
most common AEs: 
diarrhoea, nausea, 
vomiting, 
hyperglycaemia, fatigue, 
and cough 
 
80% of certitinib vs 
45% of chemotherapy 
patients required dose 
adjustment or 
interruption due to GI 
or hepatotoxicity   
susceptible patient 
groups: long QT 
syndrome, CHF, 
arrhythmias, hepatic 
impairment 
ceritinib may cause 
genotoxicity and foetal 
harm 
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Table 2: Most frequent adverse events regardless of study drug relationship of ASCEND-4 [6, 10, 27] 
 
Adverse Event (according  
to CTCAE version 4.03) 
 
Ceritinib  
(n = 189) 
Chemotherapy  
(n = 175) 
 All grades 
n (%) 
Grade 3 or 4 
n (%) 
All grades 
n (%) 
Grade 3 or 4 
n (%) 
Any AE 189 (100) 148 (78) 170 (97) 108 (62) 
Diarrhoea 160 (85) 10 (5) 19 (11) 2 (1) 
Nausea 130 (69) 5 (3) 97 (55) 9 (5) 
Vomiting 125 (66) 10 (5) 63 (36) 10 (6) 
ALT increased 114 (60) 53 (31) 38 (22)  5 (3) 
AST increased 100 (53) 32 (17) 34 (19) 3 (2) 
Hyperglycaemia 100 (53) 19 (10) 117 (67) 18 (10) 
Increased amylase 70 (37) 15 (8) 75 (43) 9 (5) 
GGT increased 70 (37) 54 (29) 18 (10) 3 (2) 
Decreased appetite 64 (34) 2 (1) 55 (31) 2 (1) 
Blood ALP increased 55 (29) 14 (7) 8 (5)  1 (1) 
Fatigue 55 (29) 8 (4) 52 (30) 5 (3) 
Abdominal pain 47 (25) 4 (2) 13 (7) 0 (0) 
Cough 46 (24) o (0) 28 (16)  0 (0) 
Weight decrease 45 (24) 7 (4) 26 (15) 1 (1) 
Blood creatinine increased 42 (22) 4 (2) 17 (10) 0 (0) 
Upper abdominal pain 39 (21) 3 (2) 10 (6) 0 (0) 
Non-cardiac chest pain 38 (20) 2 (1) 17 (10) 1 (1) 
Back pain 36 (19) 3 (2) 32 (18) 4 (2) 
Constipation 36 (19) 0 (0) 38 (22) 0 (0) 
Pyrexia 34 (18) 0 (0) 24 (14) 2 (1) 
Asthenia 33 (18) 5 (3) 36 (21) 6 (3) 
Headache 31 (16) 0 (0) 21 (12) 2 (1) 
Thrombocytopenia 31 (16) 1 (1) 67 (38) 9 (5) 
Dyspnoea 29 (15) 4 (2) 35 (20) 11 (6) 
Anaemia 28 (15) 4 (2) 62 (35) 13 (7) 
Increased lipase 25 (13) 11 (6) 13 (7) 2 (1) 
Prolonged QT interval 23 (12) 5 (3) 2 (1) 2 (1) 
Neutropenia 9 (5) 1 (1) 38 (22) 19 (11) 
WBC count decreased 7 (4) 0 (0) 31 (18) 7 (4) 
Pericarditis 7 (4) 3 (2) 4 (2) 2 (1) 
Abbreviations: AE = adverse event, ALP = alkaline phosphatase, ALT = alanine aminotransferase, AST = aspartate 
aminotransferase, CTCAE = common terminology for cancer adverse events, GGT = gamma-glutamyltransferase, WBC = 
white blood cell 
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7.2 Clinical effectiveness and safety –  
Further studies 
ASCEND-1 (NCT01283516) is a multicentre, open-label, phase 1 trial inves-
tigating the efficacy of critinib (750 mg/day until disease progression or tox-
icity) in 255 patients, of whom 246 had ALK-rearrangements [8, 30, 31]. Ap-
proximately 67% of ALK-positive NSCLC patients had received at least two 
prior treatment regimens, and 66% had received prior ALKi treatment.  
At a median follow up of 11.1 months (IQR 6.7–15.2), an overall response 
was reported in 60 (72% [95% CI 61–82]) of 83 ALKi-naïve patients and 92 
(56% [95% CI 49–64]) of 163 ALKi-pre-treated patients. Median DOR was 
17.0 months (95% CI 11.3–NE) in ALKi-naïve patients and 8.3 months (95% 
CI 6.8–9.7) in ALKi-pre-treated patients. Median PFS was 18.4 months 
(95% CI 11.1–NE) in ALKi-naïve patients and 6.9 months (95% CI 5.6–8.7) 
in ALKi-pre-treated patients. Of 94 patients with retrospectively confirmed 
BM and at least one post-baseline magnetic resonance imaging (MRI) or CT 
tumour assessment, intracranial disease control (IDCR) was reported in 15 
(79% [95% CI 54–94]) of 19 ALKi-naïve patients and 49 (65% [95% CI 54–
76]) of 75 ALKi-pre-treated patients. Of the 94 patients, 11 had measurable 
brain lesions and no previous brain radiotherapy, six achieved a partial in-
tracranial response. Serious AEs were reported in 117 (48%) of 246 patients. 
The most common grade 3 or 4 events were increased ALT (73 [30%]), in-
creased AST (25 [10%]), diarrhea (15 [6%]) and nausea (15 [6%]). Two on-
treatment deaths occurred, one due to interstitial lung disease and one from 
ischaemic hepatitis [30].  
ASCEND-3 (NCT01685138) is a multicentre, open-label, phase II trial that 
evaluates the safety and efficacy of ceritinib (750 mg/day) in 124 ALKi-naïve 
patients with ALK-rearranged NSCLC [32]. Study participants had a medi-
an age of 56 (27–82), 40.3% were male, 59.7% were Asian and 38.7% were 
Caucasian; 40.3% had BM, of which 46% had no prior brain radiation. The 
median time from diagnosis to treatment was 13.5 (1.0–283.1) months; me-
dian exposure duration was 8.0 (0.1-16.2 months; and median follow-up was 
8.3 (0.6-16.3) months.  
At baseline, 10 patients had investigator-assessed measurable BM; IDCR 
was 80% (95% CI 44.4-97.5). Ceritinib showed brain response in six patients 
with BM without prior brain radiotherapy. Overall response was reported in 
29 (58.0% [95% CI 43.2–71.8]) of patients with and 50 (67.6% [95% CI 55.7–
78.0]) without BM. Whole body disease control rate (DCR) was 43 (86.0% 
[73.3–94.2] in patients with and 68 (91.9% [95% CI 83.2-97.0]) in those 
without BM. Median DOR was 9.1 (95% CI 7.5–NE) months in patients 
with BM and 10.8 (95% CI 9.3–10.8) months in those without. Median PFS 
was 10.8 (95% CI 7.3–NE) months in patients with and 11.1 (95% CI 9.2–
12.8) months in those without BM. The most common AEs were diarrhoea 
(83%), nausea (74%) and vomiting (66.9%); 7.3% of patients discontinued 
due to AEs 
 
 
ASCEND-1: 83 ALKi-
naïve and 163 ALKi-pre-
treated ALK-positive 
patients 
median ORR: 72% of 
ALKi-naïve and 56% of 
ALKi-pre-treated 
patients; DOR 17 
months vs 8.3 months 
median PFS: 18.4 
months in ALKi-naïve 
and 6.9 months in ALKi-
pre-treated patients 
ICDR: 79% of ALKi-
naïve and 65% of ALKi-
pre-treated patients 
ASCEND-3: 124 ALKi-
naïve ALK-positive 
NSCLC patients given 
ceritinib 750 mg/day 
IDCR: 80% 
ORR: 58% of patients 
with and 67.6% of 
patients without BM; 
median DOR: 9.1 vs 10.8 
months 
median PFS: 10.8 
months in patients with 
and 11.1 months in those 
without BM 
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8 Estimated costs 
A0021: What is the reimbursement status of ceritinib? 
In Austria, ceritinib is available as 150-mg hard capsules in packages of 150 
pieces. One package of 150 150-mg capsules is available for € 5,355.30 (ex-
factory price). At the recommended dose of 750 mg daily, the cost for 
ceritinib treatment would be € 3,748.71 per 21-day cycle [26]. A median du-
ration of 16.6 months (IQR 7.5–20.9 months) of ceritinib treatment would 
cost approximately € 62,230.00. Since ceritinib is indicated for ALK-positive 
NSCLC patients, additional costs in the range of approximately $US 68.89 
for IHC or $US 279.46 for parallel FISH and IHC will be incurred for ALK-
testing [38]. 
 
 
9 Ongoing research 
Several studies are ongoing to investigate ceritinib as monotherapy follow-
ing pre-treatment with chemotherapy or ALKi, and in combination with 
immune checkpoint inhibitors or other anticancer agents used to treat ad-
vanced NSCLC. A search of clinicaltrials.gov using search terms “ceritinib” 
and “NSCLC” yielded 18 registered studies (two phase III, seven phase II, 
three phase I/II, four phase I, an observational study and an expanded ac-
cess protocol). A search of the EU Clinical Trials Register yielded six studies 
(three were already identified in clinicaltrials.gov, (one phase IV, two phase 
III, one phase II, and two phase I/II). Most studies are industry-sponsored or 
conducted in collaboration with industry.  
Selected ongoing phase IV, III and II studies for ALK-arranged NSCLC pa-
tients:  
 NCT02584933: A phase IV, open-label, roll-over study in patients 
with ALK-positive malignancies who have completed a prior No-
vartis-sponsored ceritinib study. Estimated primary completion 
date is December 2020.  
 NCT02450903: A phase II, interventional study to investigate ORR, 
DOR, PFS and OR to ceritinib in ALK-positive NSCLC patients 
previously treated with the ALKi alectinib. Estimated primary 
completion date is August 2017.  
 NCT01964157: A phase II, open-label study of ceritinib in 32 pa-
tients with ROS1-rearranged NSCLC. Estimated primary comple-
tion date is December 2017.  
 NCT01828112: ASCEND-5 is a phase III, randomized, open-label 
trial comparing ceritinib versus chemotherapy in ALK-positive pa-
tients previously treated with platinum-based chemotherapy and 
crizotinib. Estimated primary completion date is August 2018.  
 NCT02292550: A phase I/II, non-randomized study of ceritinib in 
combination with the CDK4/6 inhibitor LEE011 in patients with 
€ 3,748.71 per 21-day 
cycle 
25 registered trials; 2 
industry-sponsored 
phase III studies 
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ALK-positive NSCLC. Estimated primary completion date is Octo-
ber 2018.  
 NCT02336451: ASCEND-7 is a phase II, interventional trial to 
evaluate the efficacy and safety of ceritinib in patients with ALK-
positive metastatic NSCLC to the brain and/or to leptomeninges. 
Estimated primary completion date is December 2018.  
 NCT02513667: A phase II, open-label, interventional study investi-
gating ceritinib in combination with sterotactic ablative radiation-
for metastatic lung adenocarcinoma. Estimated primary completion 
date is August 2019.  
 NCT03087448: A phase I/II, interventional study to investigate 
ceritinib plus trametinib in patients with advanced ALK-positive 
NSCLC. Estimated primary completion date is March 2021. 
 
 
 
10 Discussion 
In 2014–2015, ceritinib was approved, by the EMA [11] and the US FDA [7], 
for the treatment of adults with ALK-positive advanced NSCLC previously 
treated with crizotinib. Initial approval was based on the results of the phase 
I, single-arm, open-label ASCEND-1 trial [8]. In January 2017, ceritinib was 
granted FDA-breakthrough therapy designation as first-line treatment for 
ALK-positive NSCLC with BM. On May 18, 2017, CHMP provided a posi-
tive opinion on ceritinib monotherapy as first-line treatment for adults with 
ALK-positive advanced NSCLC [12]. Similarly, on May 26, 2017, the FDA 
expanded use of ceritinib as first-line treatment for patients with ALK-
positive metastatic NSCLC as detected by an FDA-approved test [9]. The 
first-line approval of ceritinib was based on results from the phase III AS-
CEND-4 trial [10].  
ASCEND-4, a randomized, open-label, phase III multicentre study com-
pared the safety and efficacy of ceritinib (750 mg/day, fasted) versus plati-
num-based chemotherapy in 376 untreated patients with advanced ALK-
positive non-squamous NSCLC [10]. Compared with chemotherapy, 
ceritinib increased median PFS by 8.5 in the ITT population as assessed by 
the BIRC. The PFS benefit of ceritinib over chemotherapy was reported in 
patients regardless of the presence or absence of baseline BM. Compared 
with chemotherapy, ceritinib improved median PFS by 4 months in patients 
with BM, and by 17.5 months in those without. The ORR was 72.5% for 
ceritinib versus 26.7% for chemotherapy, where ceritinib conferred an in-
crease of 12.8 months in DOR. At the time of analysis, OS data were not ma-
ture having accrued 107 (42%) of the required events for final OS analysis. 
Estimated OS rates at 24 months were 70.6% for ceritinib and 58.2% for 
chemotherapy recipients. Ceritinib significantly improved the general QoL 
and prolonged time to deterioration for cancer-specific symptoms compared 
with chemotherapy.  
indication approved by 
the FDA 
 
 
 
positive CHMP opinion 
ASCEND-4: 
improvement in PFS 
(+8.5 months), 
improved ORR, 
immature OS data 
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The most common AEs were diarrhoea, nausea, vomiting and increased ALT 
in ceritinib recipients and nausea, vomiting and anaemia in chemotherapy 
recipients. AEs requiring dose adjustment or interruption were reported in 
80% of ceritinib patients versus 45% of patients receiving chemotherapy. GI 
toxicity accounted for 50 (28%) of dose adjustments or interruptions in the 
ceritinib group including vomiting (15%), diarrhoea (13%), nausea (12%), 
and treatment discontinuation in 2% of patients.   
The clinical efficacy and safety results of ASCEND-4 are consistent with 
phase I and II data, from the ASCEND-1 [8, 30, 31] and ASCEND-3 trials 
[32], where ceritinib prolonged the median PFS to 18.4 months in each 
study.  Consistency in the PFS benefit of ceritinib over subgroups regardless 
of the presence or absence of baseline BM observed in ASCEND-4 is in 
keeping with similar findings from ASCEND-3. However, none of these tri-
als confirm whether the increase in PFS actually confers a meaningful 
change in OS. Diarrhoea, nausea, vomiting, and elevated ALT were also 
commonly reported AEs in phase I and II trials.  
Several methodological limitations of the ASCEND-4 trial compromise in-
ternal and external validity. While patients were randomized 1:1 to ceritinib 
or chemotherapy via an interactive response system, allocation concealment 
was not maintained and may influence how participants were assigned to a 
given group. Internal validity may be compromised in an open-label study 
where patients and treating physicians are aware of treatment allocation in-
troducing potential for bias in the estimate of effect of an intervention. 
While endpoints were assessed by the BIRC, the outcome of ICBR was add-
ed post hoc leading to possible selective reporting.  
Given the non-curative setting of ceritinib and the statistically significant 
primary endpoint PFS we applied Form 2b of the ESMO-MCBS in order to 
assess whether ceritinib satisfies the criteria for a “meaningful clinical bene-
fit” (score 4 or 5). Both the original as well as the adapted version of the 
MCBS were applied [34, 35]. The application of the ESMO-MCBS to the 
ASCEND-4 study resulted in a grade 4 and 3 in the original and the adapted 
version of the ESMO-MCBS, respectively. Therefore, ceritinib only leads to 
a meaningful clinical benefit in the original scale, but not in the adapted 
framework. This difference occurs due to the higher implication of toxicities 
in the adapted ESMO-MCBS.  
Results of the ASCEND-4 study hold several limitations. While first-line 
platinum-based chemotherapy was standard of care for advanced NSCLC at 
inception of this study, crizotinib has since been approved as first-line 
treatment for patients with ALK-positive NSCLC based on results from the 
PROFILE 1014 study [39]. As crizotinib is now standard care for ALK-
positive NSCLC, it may have been a more appropriate comparator for the 
study. In the ASCEND-4 study, 78% of ceritinib patients experience grade 3 
or 4 AEs, and 80% required dose adjustment or interruption. In contrast 
54% of crizotinib-treated patients in PROFILE experienced grade 3 or 4 AE 
of which 41% required dose interruption and 6% required dose reduction. 
Due to the potential for drug toxicity, patients may lend preference to initial 
treatment with crizotinib before transitioning to ceritinib following disease 
progression. Sequential treatment with crizotinib followed by ceritinib was 
associated with a comparable median PFS of 17.4 months in a retrospective 
analysis [40].  
treatment-related AEs 
any grade were more 
common in the ceritinib 
group 
consistent efficacy and 
safety results with 
former studies 
high risk of bias: unclear 
allocation concealment, 
open-label study, 
possible selective 
outcome reporting 
ESMO-MCBS 
original: grade 4 
adapted: grade 3 
limitations due to 
comparator 
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The ALEX trial is currently underway to compare the second-generation 
ALKi alectinib versus crizotinib in patients with crizotinib-naïve, ALK-
positive NSCLC [41]. At interim analysis, alectinib improved PFS com-
pared to crizotinib with notable benefit in patients with BM in whom medi-
an PFS was not reached versus 10.2 months. At primary analysis, 12-month 
PFS was significantly higher with alectinib compared to crizotinib (68% 
[95% CI 61-76] versus 49% [95% CI 40-57]; HR for disease progression or 
death was 0.47 [95% CI 0.34-0.65; p<0.001); and median OS was not estima-
ble in either group]. CNS progression was more common the cizotinib group 
than the alectinib group (68 patients (45%) vs 18 (12%); HR 0.16 [95% CI 
0.10-0.28; p<0.001]) [42]. In ASCEND-4, median PFS with ceritinib in pa-
tients with BM was 10.7 months suggesting alectinib may offer greater brain 
permeability and less GI toxicities than ceritinib. However, a direct compar-
ison would be necessary to evaluate the more beneficial efficacy and safety 
profile for ALK-positive NSCLC patients. Other second- and third-
generation ALKi are under evaluation with broader activity than ceritinib or 
alectinib against ALK resistance mutations and greater CNS activity raising 
the possibility of more durable responses in the first-line setting.  
The cost of one package of 150 150 mg capsules of ceritinib is € 5,355.30 (ex-
factory price). At the recommended dose of 750 mg daily, the cost for 
ceritinib treatment would be € 3,748.71 per 21-day cycle. In contrast, crizo-
tinib treatment for 21 days would amount about € 4,000 and alectinib ap-
proximately € 4,100 [26]. A median duration of 16.6 months (IQR 7.5–20.9 
months) of ceritinib treatment would cost approximately € 62,230.00.  
Overall, the ASCEND-4 phase III randomised study reports that ceritinib 
improves PFS and DOR in patients with advanced ALK-positive NSCLC 
regardless of the presence or absence of baseline BM, relative to platinum-
based chemotherapy. While ceritinib also improved general QoL and pro-
longed time to deterioration of cancer-specific symptoms compared to 
chemotherapy, higher rates of treatment-related clinically relevant AEs may 
incur higher cost with continuous treatment. However, results from the AS-
CEND-4 study hold limited external validity as crizotinib is now standard 
care over chemotherapy for ALK-positive NSCLC and it is unclear whether 
the increase in PFS actually confers a meaningful change in OS. Even in the 
absence of head-to-head comparison trials and despite the lack of OS bene-
fit, oncologists may chose ceritinib as first-line therapy for patients with ad-
vanced ALK-positive NSCLC if it is more active than other drugs even if it 
is less tolerable. Comparative studies of other second- and third-generation 
ALKi are ongoing which may offer further first-line options with broader ac-
tivity against resistant mutations, lesser toxicity and greater CNS activity 
than ceritinib.  
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new second- and third-
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cycle; € 3,748.71 per 16.6 
months of treatment 
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Table 3: Benefit assessment based on original ESMO-MCBS and adapted benefit assessment based on adapted ESMO-MCBS [34, 35] 
ESMO-
MCBS 
Active  
substance Indication Intention PE Form 
MG standard 
treatment 
Efficacy Safety 
AJ FM 
MG months 
HR 
(95% CI) 
Score calculation PM Toxicity QoL 
Adapted 
ESMO-
MCBS 
Ceritinib NSCLC (1st-line) 
Not 
curative PFS 2b >6 months +8.5 
0.55 
0.42–0.73 
HR ≤0.65 AND  
Gain ≥3 months 
3 
+16% grade  
3–4 AEs (-1)A 
impr. QoL 
(+1)B 
-1/+1 3 
Original 
ESMO-
MCBS 
Ceritinib NSCLC 
(1st-line) 
Not 
curative 
PFS 2b >6 months +8.5 0.55 
0.42–0.73 
HR ≤0.65 AND  
Gain ≥3 months 
3 x 
impr. QoL 
(+1)B  
+1 4 
Abbreviations: AJ = Adjustments, CI = confidence interval, FM = final adjusted magnitude of clinical benefit grade, HR = hazard ratio, m = months, MG = median gain, ND = no difference, NSCLC = non-small lung cancer, 
PE = primary endpoint, PM = preliminary magnitude of clinical benefit grade, PFS = progression-free survival, QoL = quality of life 
 
DISCLAIMER 
The scores achieved with the ESMO Magnitude of Clinical Benefit Scale are influenced by several factors: by the specific evaluation form used, by the confidence interval (CI) of the endpoint 
of interest, and by score adjustments due to safety issues. Ad form: Every individual form measures a different outcome. The meaning of a score generated by form 2a is not comparable to the 
exact same score resulting from the use of form 2c. To ensure comparability, we report the form that was used for the assessment. Ad CI: The use of the lower limit of the CI systematically fa-
vours drugs with a higher degree of uncertainty (broad CI). Hence, we decided to avoid this systematic bias and use the mean estimate of effect. Ad score adjustments: Cut-off values and out-
comes that lead to an up- or downgrading seem to be arbitrary. In addition, they are independent of the primary outcome and, therefore, a reason for confounding. Hence, we report the adjust-
ments separately. 
 
                                                             
A
 Downgrade due to a negative difference of at least 10% in grade ≥3 AEs 
B
 Upgrade due to statistically significant positive difference in QoL 
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12 Appendix  
Table 4: Characteristics of the ASCEND-4 trial 
Title: First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged NSCLC [10, 27, 29] 
Study identifier NCT01828099, CLDK378A2301, EudraCT2013-000319-26, ASCEND-4 
Design Multicentre (28 countries, 134 centres), randomised, open-label, interventional, phase III study 
Duration of main phase: August 19, 2013-May 11, 2015: assessed eligibility of 425 pa-
tients; randomized 376 patients  
Interim analysis: March 23, 2015 85 PFS events 
Data cut-off: June 24, 2016 when 202 PFS events were ob-
served by BIRC 
Median duration of follow-up: 19.7 months (randomiza-
tion to cut-off) 
Duration of Run-in phase: not applicable 
Duration of Extension phase: ET phase for 80 patients that crossed over to ceritinib af-
ter discontinuing chemotherapy: cycle 1 (28 days), subse-
quent cycles (21 days), end of treatment visit  
Hypothesis 
Superiority 
The study was designed to evaluate the efficacy, safety and PROs of ceritinib versus platinum-pemetrexed 
doublet followed by pemetrexed maintenance in untreated, advanced ALK-rearranged NSCLC patients.  
Funding Novartis Pharmaceuticals Corporation 
Treatment groups Ceritinib 
(n=189 full analysis; 189 treated, n=189 
safety analysis) 
750 mg/day orally (given in a fasted state) until disease pro-
gression or unacceptable toxicity 
Platinum-based chemotherapy 
(n=187 full analysis; 175 safety analysis) 
n=87 pemetrexed + cisplatin 
n=88 pemetrexed + carboplatin 
n=127 pemetrexed maintenance 
Cisplatin 75 mg/m2 or carboplatin AUC 5-6 plus pemetrexed 500 
mg/m2 IV every 21 days for 4 cycles followed by maintenance 
pemetrexed (500 mg/m2) every 21 days until disease progres-
sion according to RECIST 1.1 (confirmed by BIRC) or unaccepta-
ble toxicity 
Notes 
Treated beyond progression if patients continued to derive in-
vestigator-assessed clinical benefit  
 
Ceritinib patients were allowed a maximum of three dose re-
ductions (150 mg per reduction to 300 mg/day) 
 
Chemotherapy patients (n=80) were crossed over to ceritinib 
when they had BIRC-confirmed, RECIST-defined progressive 
disease [27] 
Endpoints and defini-
tions 
 
Progression-free survival  
(primary endpoint) 
 
PFS 
Time from date of randomization first radiologically document-
ed disease progression (as assessed by BIRC per RECIST 1.1) or 
death by any cause (33 months) 
Overall survival 
(secondary endpoint) 
OS 
Time from date of randomization to death by any cause (33 
months) 
Overall response rate 
(secondary endpoint) 
ORR 
Proportion of patients with a best overall response defined as 
CR or PR (as evaluated by BIRC and by investigator assessment 
per RECIST 1.1) (33 month) 
Duration of response 
(secondary endpoint) 
DOR Time from date of first documented CR or PR to first docu-
mented disease progression or death by any cause (33 months) 
Time to response 
(secondary endpoint) 
TTR 
Time from date of randomization to first documented response 
(CR or PR) (as assessed by BIRC and investigator) (33 months) 
Overall intracranial response 
rate 
(secondary endpoint) 
OIRR 
Proportion of patients with a best overall confirmed response 
of CR or PR in the brain per modified RECIST 1.1 as assessed by 
BIRC neuro-radiologist 
Duration of intracranial re-
sponse  
(secondary response) 
DOIR 
Among patients with confirmed intracranial response (PR or 
CR), DOIR is defined as the DOR based on target, non-target le-
sion (and new lesion, if applicable) assessments in the brain and 
calculated from time of first documented intracranial response 
(PR or CR) to date of first intracranial PD or death by any cause 
per modified RECIST 1.1 (33 months) 
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Title: First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged NSCLC [10, 27, 29] 
Study identifier NCT01828099, CLDK378A2301, EudraCT2013-000319-26, ASCEND-4 
Intracranial clinical benefit rate 
(secondary endpoint) 
ICBR 
Proportion of patients with a best overall response of CR or PR, 
or an overall lesion response of SD or non-CR/non-PD (for pa-
tients with non-measurable disease) or better which lasts for a 
minimum time duration in the brain per modified RECIST 1.1 as 
assessed by BIRC neuro-radiologist.  ICBR was added as post-
hoc analyses to be calculated at 12 weeks, 18 weeks and 24 
weeks after randomization among patients with measurable 
BM at baseline and separately in patients having measurable or 
non-measurable BM at baseline. (33 months) 
Notes 
Tumour assessments were conducted at baseline, every 6 weeks after cy-
cle 1 day 1 through month 33, every 9 weeks and at end of treatment. Pa-
tients who progressed were followed for survival every 12 weeks until 
death, loss to follow-up or consent withdrawal 
Database lock Last updated: November 3, 2016 
Results and Analysis  
Analysis description Primary Analysis 
ITT: Primary endpoint was BIRC assessed PFS based on all randomly assigned patients (the full analysis set). 
Efficacy analyses were done based on the full analysis set. All safety analyses were done based on the safety 
set that included all patients who received at least one dose of study drug.  
Given a median PFS of 8 months in chemotherapy patients, a 38% risk reduction in HR was expected with 
ceritinib. Assuming a HR of 0.62, about 205 PFS events were required for 90% power at a one-sided 2.5% 
level of significance to reject the null hypothesis using a log-rank test and a two-look group sequential design. 
Approximately 348 patients were needed for 1:1 randomization.  
Interim analysis was planned for the primary endpoint PFS as per BIRC assessment when 72 PFS events of the 
targeted 205 (35%) PFS events were documented. At interim analysis March 23, 2015, 85 PFS events (41.4%) 
were observed. OS analyses were to be done if the primary endpoint was statistically significant using a group 
sequential design with three interim analyses and final analysis at approximately 253 deaths (one-sided 2.5% 
significance). A Cox regression model stratified by randomization stratification factors was used to estimate 
the HR, together with 95% CIs based on the Wald test. A stratified log-rank test (randomization stratification 
factors) was used for treatment comparisons of PFS and OS. The statistical basis for efficacy was the statisti-
cal significance (at the 2.5% one-sided level of significance) for PS in favour of ceritinib. Kaplan-Meier was 
used to analyse time-to-event endpoints.  
Analysis population  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inclusion  Adults (aged ≥18 years) with histologically/cytologically confirmed LA or 
metastatic non-squamous ALK-rearranged NSCLC assessed by the Ven-
tana anti-ALK (D5F3) IHC test (performed at Novartis designated central 
laboratory) 
 Newly diagnosed stage IIIB (non-candidates for definitive multimodality 
therapy) or stage IV NSCLC or relapsed LA or metastatic NSCLC untreated 
with any systemic anti-cancer therapy (e.g.. cytotoxic drugs, monoclonal 
antibody therapy, crizotinib or other ALK inhibitors, or other targeted 
therapies, either experimental or not), except for neo-adjuvant or adju-
vant therapy  
 Measurable disease as per RECIST 1.1, WHO performance status 0-2 
 Asymptomatic or neurologically stable BM (≥2 weeks) 
Exclusion  Hypersensitivity to any excipients of ceritinib  
 Hypersensitivity to platinum-containing drugs, pemetrexed or any known 
excipients of these drugs. 
 History of interstitial lung disease or pneumonitis, including radiation 
pneumonitis; carcinomatous meningitis, concurrent malignancy or malig-
nant disease other than NSCLC diagnosed or requiring therapy within the 
past 3 years (except resected basal cell, squamous cell, or carcinoma in 
situ); uncontrolled heart disease or cardiac event (within 6 months); im-
paired gastrointestinal function or gastrointestinal disease that could al-
ter ceritinib absorption.  
 Thoracic radiotherapy to lung fields ≤4 weeks before starting the study 
and radiotherapy-related toxicities  
 Major surgery within 4 weeks before (2 weeks for resection of BM) start-
ing study treatment or recovering from side-effects  
 Symptomatic CNS metastases, neurologically unstable or requires increas-
ing doses of steroids within the 2 weeks prior to screening  
 
Characteristics 
 
Ceritinib 
(n = 189) 
Chemotherapy 
(n = 187) 
All patients 
(n = 376) 
Median age, years (range)  55 (22–81) 54 (22–80) 54 (22–81) 
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Title: First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged NSCLC [10, 27, 29] 
Study identifier NCT01828099, CLDK378A2301, EudraCT2013-000319-26, ASCEND-4 
Analysis population 
(continuation) 
Male sex (%) 87 (46) 73 (39) 160 (43) 
Race 
Asian 
Caucasian 
Other 
 
76 (40) 
104 (55) 
9 (5) 
 
82 (44) 
98 (52) 
7 (4) 
 
158 (42) 
202 (54) 
16 (4) 
WHO PS 
0 
1 
2 
 
69 (37) 
107 (57) 
13 (7) 
 
70 (37) 
105 (56) 
11 (6) 
 
139 (37) 
212 (56) 
24 (6) 
Smoking history 
Current smoker 
Ex-smoker 
Never smoked 
 
15 (8) 
66 (35) 
108 (57) 
 
15 (8) 
50 (27) 
122 (65) 
 
30 (8) 
116 (31) 
230 (61) 
Histology/cytology,  
n (%) 
Adenocarcinoma 
 
 
180 (95) 
 
 
183 (98) 
 
 
363 (97) 
Stage at entry, n (%) 
LA stage IIIb 
Metastatic stage IV 
 
9 (5) 
180 (95) 
 
5 (3) 
182 (97) 
 
14 (4) 
363 (96) 
Metastatic site 
Bone 
Brain 
Liver 
 
77 (41) 
59 (31) 
34 (18) 
 
80 (43) 
62 (33) 
39 (21) 
 
157 (42) 
121 (32) 
73 (19) 
Previous therapy 
Surgery 
Radiotherapy 
Brain radiotherapy 
BR to randomization ≤3 
months 
 
44 (23) 
37 (20) 
24 (13) 
 
22/24 (92) 
 
43 (23) 
40 (21) 
26 (14) 
 
23/26 (89) 
 
NR 
77 (21) 
50 (13) 
 
45/50 (90) 
Chemotherapy 
Adjuvant 
Neoadjuvant 
 
10 (5) 
0 
 
7 (4) 
2 (1) 
 
17 (5) 
2 (1) 
Prior regimens of chemo-
therapy 
1 
 
 
10 (5) 
 
 
9 (5) 
 
 
19 (5) 
Abbreviations: AE = adverse events, ALK = anaplastic lymphoma kinase; BIRC = blinded independent review committee, BM = brain metastases, BR = 
brain radiotherapy, CNS = central nervous system, CR = complete response, CTDAE = Common Terminology Criteria for Adverse Events, DCR = disease 
control rate, DOIR = duration of intracranial response, DOR = duration of response, ET = extension treatment, HR = hazard ratio, ICBR = intracranial 
clinical benefit rate, IDCR = intracranial disease control rate, IHC = immunohistochemistry, IV = intravenous, LA = locally advanced, NR = not 
reported, NSCLC = non-small cell lung cancer, OIRR = overall intracranial response rate; ORR = overall response rate, OS = overall survival; PD = 
progression of disease, PFS = progression-free survival, PR = partial response, PROs = patient reported outcomes, PS = performance status, RECIST = 
Response Evaluation Criteria in Solid Tumours , SD = stable disease, TTR = time to response 
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Table 5: Risk of bias assessment on study level is based on EUnetHTA (Internal validity of randomized controlled trials) [33] 
Criteria for judging risk of bias  Risk of bias 
Adequate generation of randomisation sequence: 1:1 ceritinib vs IV chemotherapy via interactive 
response technology; stratified by WHO performance status (0 vs 1-2), previous neoadjuvant or 
adjuvant chemotherapy (yes vs no), and BM as per investigators’ assessment at screening (present 
vs absent) 
unclear 
Adequate allocation concealment unclear 
Blinding 
Patient: open-label, patients unmasked to treatment assignment yes 
Treating Physician: open-label, investigators were unmasked to treatment as-
signment 
yes 
Outcome assessment: open-label, tumour response assessed by investigator and 
BIRC; intracranial response assessed based on images collected for the BIRC by 
and independent central neuro-radiologist (from BIRC) who was masked to 
treatment; sponsor personnel remained masked until database lock for primary 
analysis (except to view individual patient data on case report forms for phar-
macokinetics data, study drug dose and concomitant medications) 
no 
Selective outcome reporting unlikely: outcomes reported as specified in protocol; withdrawals and 
drop-outs reported 
no 
No other aspects which increase the risk of bias: Industry funded the study, assisted with study 
design, contributed to data interpretation, writing, reviewing, revising report, medical writer em-
ployed by the funder.  
high 
Risk of bias – study level high 
Abbreviations: BIRC = blinded independent review committee, BM = brain metastases 
